Anika Therapeutics (Anika Therapeutics) FCF Margin % : 4.18% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Anika Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $1.8 Mil. Anika Therapeutics's Revenue for the three months ended in Dec. 2023 was $43.0 Mil. Therefore, Anika Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 4.18%.

As of today, Anika Therapeutics's current FCF Yield % is -1.90%.

The historical rank and industry rank for Anika Therapeutics's FCF Margin % or its related term are showing as below:

ANIK' s FCF Margin % Range Over the Past 10 Years
Min: -4.33 Med: 19.08 Max: 36.39
Current: -4.33

During the past 13 years, the highest FCF Margin % of Anika Therapeutics was 36.39%. The lowest was -4.33%. And the median was 19.08%.

ANIK's FCF Margin % is ranked better than
53.28% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: -7.14 vs ANIK: -4.33

Anika Therapeutics FCF Margin % Historical Data

The historical data trend for Anika Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics FCF Margin % Chart

Anika Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

29.82

8.77

2.20

-1.97

-4.33

Anika Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-5.17	-13.20	-22.01	13.85	4.18

Competitive Comparison of Anika Therapeutics's FCF Margin %

For the Medical Instruments & Supplies subindustry, Anika Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anika Therapeutics's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's FCF Margin % falls into.

Anika Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Anika Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-7.215	/	166.662
	=	-4.33 %

Anika Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1.798	/	42.971
	=	4.18 %

Anika Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anika Therapeutics (Anika Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AKP:Germany

Address

32 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.anika.com

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Executives

Anne Nunes	officer: SVP, Chief Operations Officer	32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti	director	600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran	officer: EVP, General Counsel, Corp Sec	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz	officer: EVP, CFO, Treasurer	C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land	director
Stephen Richard	director	C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop	officer: EVP Business Development	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung	officer: CFO	ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson	director	1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling	officer: President	501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767